IRADIMED Files 8-K on Financial Results, Operations
Ticker: IRMD · Form: 8-K · Filed: Feb 8, 2024 · CIK: 1325618
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K
TL;DR
**IRADIMED just dropped an 8-K on financial results, get ready for potential stock movement.**
AI Summary
IRADIMED CORPORATION filed an 8-K on February 8, 2024, to announce its results of operations and financial condition. This filing, under Items 2.02 and 9.01, indicates the company is providing an update on its financial performance. For investors, this matters because it offers a timely glimpse into the company's health and future prospects, potentially influencing stock price based on whether the results meet or exceed expectations.
Why It Matters
This filing provides investors with crucial, up-to-date financial information, allowing them to assess IRADIMED's performance and make informed decisions about their investment.
Risk Assessment
Risk Level: medium — The risk level is medium because while the filing itself is procedural, the undisclosed financial results could significantly impact the stock, either positively or negatively.
Analyst Insight
A smart investor would await the full disclosure of the financial results mentioned in this 8-K before making any significant investment decisions regarding IRADIMED CORPORATION, as the details will dictate the true impact.
Key Players & Entities
- IRADIMED CORPORATION (company) — the registrant filing the 8-K
- February 8, 2024 (date) — date of earliest event reported and filing date
- 001-36534 (string) — Commission File Number for IRADIMED CORPORATION
- 1025 Willa Springs Dr., Winter Springs, FL 32708 (string) — business address of IRADIMED CORPORATION
- 407-677-8022 (string) — business phone number of IRADIMED CORPORATION
Forward-Looking Statements
- IRADIMED's stock price will react significantly to the detailed financial results once they are fully disclosed. (IRADIMED CORPORATION) — high confidence, target: within 1 week of full disclosure
- Analysts will issue updated ratings or price targets for IRADIMED based on the financial performance reported. (IRADIMED CORPORATION) — medium confidence, target: within 2 weeks of full disclosure
FAQ
What is the purpose of IRADIMED CORPORATION's 8-K filing on February 8, 2024?
The 8-K filing by IRADIMED CORPORATION on February 8, 2024, is to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' under Item 2.02 and Item 9.01, respectively.
What is the earliest event reported date for this 8-K filing?
The date of the earliest event reported for this 8-K filing is February 8, 2024.
Where is IRADIMED CORPORATION's principal executive office located?
IRADIMED CORPORATION's principal executive office is located at 1025 Willa Springs Dr., Winter Springs, FL 32708.
What is IRADIMED CORPORATION's Commission File Number?
IRADIMED CORPORATION's Commission File Number is 001-36534.
Is IRADIMED CORPORATION an emerging growth company according to this filing?
Based on the filing, IRADIMED CORPORATION has indicated with a checkbox that it is not an emerging growth company.
Filing Stats: 509 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-02-08 08:05:40
Key Financial Figures
- $0.0001 — h registered: Common stock, par value $0.0001 IRMD NASDAQ Capital Market Item 2
Filing Documents
- irmd-20240208x8k.htm (8-K) — 35KB
- irmd-20240208xex99d1.htm (EX-99.1) — 215KB
- irmd-20240208xex99d1001.jpg (GRAPHIC) — 10KB
- 0001558370-24-000877.txt ( ) — 485KB
- irmd-20240208.xsd (EX-101.SCH) — 3KB
- irmd-20240208_lab.xml (EX-101.LAB) — 1KB
- irmd-20240208_pre.xml (EX-101.PRE) — 10KB
- irmd-20240208x8k_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 8, 2024, IRADIMED CORPORATION issued a press release (the "Press Release") announcing its financial results for the fourth quarter and full year ended December 31, 2023. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated February 8, 2024. 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IRADIMED CORPORATION Date: February 8, 2024 By: /s/John Glenn Name: John Glenn Title: Chief Financial Officer